{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:36:02Z","timestamp":1789140962962,"version":"build-2803163510"},"reference-count":10,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Oloyede and colleagues advocate for updating haematological monitoring requirements for clozapine, arguing that current protocols overestimate the risk of clozapine-induced agranulocytosis. Their research suggests that stringent monitoring may unnecessarily limit access to clozapine, a crucial treatment for resistant schizophrenia. The editorial supports calls for international consensus to carefully weigh the pros and cons of relaxing monitoring guidelines while ensuring comprehensive care for patients.<\/jats:p>","DOI":"10.1192\/bjp.2024.150","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:42:59Z","timestamp":1727926979000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":12,"title":["Clozapine monitoring requirements: is it time for an update?"],"prefix":"10.1192","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-8955","authenticated-orcid":false,"given":"Emilio","family":"Fernandez-Egea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-2566","authenticated-orcid":false,"given":"Robert A.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"S0007125024001508_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00097-X"},{"key":"S0007125024001508_ref10","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602200066X"},{"key":"S0007125024001508_ref5","unstructured":"5 Netherlands Clozapine Collaboration Group. Guideline for the use of clozapine. 2013. (https:\/\/www.clozapinepluswerkgroep.nl\/wp-content\/uploads\/2013\/07\/Guideline-for-the-use-of-Clozapine-2013.pdf)."},{"key":"S0007125024001508_ref4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.88"},{"key":"S0007125024001508_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)90206-8"},{"key":"S0007125024001508_ref1","article-title":"Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study","author":"Oloyede","journal-title":"BJPsych"},{"key":"S0007125024001508_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719000369"},{"key":"S0007125024001508_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00343-7"},{"key":"S0007125024001508_ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.44"},{"key":"S0007125024001508_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92929-N"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125024001508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:14:45Z","timestamp":1752574485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125024001508\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0007125024001508"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2024.150","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}